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Background: Lynch syndrome is the most common inherited cause of endometrial
cancer. Identifying individuals affected by Lynch syndrome enables risk-reducing
interventions including colorectal surveillance, and cascade testing of relatives.
Methods:We conducted a micro-costing study of screening all women with endometrial
cancer for Lynch syndrome using one of four diagnostic strategies combining
tumor microsatellite instability testing (MSI), immunohistochemistry (IHC), and/or MLH1
methylation testing, and germline next generation sequencing (NGS). Resource use
(consumables, capital equipment, and staff) was identified through direct observation
and laboratory protocols. Published sources were used to identify unit costs to calculate
a per-patient cost (£; 2017) of each testing strategy, assuming a National Health Service
(NHS) perspective.
Results: Tumor triagewithMSI and reflexMLH1methylation testing followed by germline
NGS of womenwith likely Lynch syndromewas the cheapest strategy at £42.01 per case.
Tumor triage with IHC and reflex MLH1 methylation testing of MLH1 protein-deficient
cancers followed by NGS of women with likely Lynch syndrome cost £45.68. Tumor
triage with MSI followed by NGS of all women found to have tumor microsatellite
instability cost £78.95. Immediate germline NGS of all women with endometrial cancer
cost £176.24. The cost of NGS was affected by the skills and time needed to interpret
results (£44.55/patient).
Ryan et al. Micro-Costs of Lynch Syndrome Screening
Conclusion: This study identified the cost of reflex screening all women with
endometrial cancer for Lynch syndrome, which can be used in a model-based
cost-effectiveness analysis to understand the added value of introducing reflex screening
into clinical practice.
Keywords: micro-costing, Lynch syndrome, endometrial cancer, genetic testing, screening
INTRODUCTION
Lynch syndrome is an inherited predisposition to a constellation
of different cancers, of which colorectal and endometrial cancer
are the most common (1). Estimates of the prevalence of Lynch
syndrome among the general population are as high as 300
per 100,000 (2). Lynch syndrome confers a lifetime risk of
endometrial cancer of 30 to 40% (3). Endometrial cancer may
be the sentinel event in women with Lynch syndrome, providing
an early diagnostic opportunity (4). Those found to have Lynch
syndrome are offered risk-reducing interventions including
colorectal surveillance to reduce cancer-specific mortality (5).
A diagnosis of Lynch syndrome enables cascade testing within
families and its identification in those who are yet to develop
cancer (6). Identified womenmay be offered prophylactic surgery
to reduce their risk of gynecological cancer (7).
Lynch syndrome arises from germline pathogenic variants
within the highly conserved mismatch repair (MMR) system.
The molecular characteristics of Lynch syndrome-associated
cancers enable tumor-based triage and targeted germline
sequencing of the MMR genes, commonly performed by next
generation sequencing (NGS). A Lynch syndrome-associated
tumor classically shows aberrant expression of associated MMR
proteins, MLH1, MSH2, MSH6 and/or PMS2, and microsatellite
instability (MSI) (8). Loss of MLH1 expression through somatic
methylation of theMLH1 promotor region is a common sporadic
event in endometrial cancer; MLH1 methylation testing is
therefore an effective way of reducing the number of women with
MLH1 loss by IHC or whose tumors are MSI-H from expensive
germline testing (9).
The National Institute for Health and Care Excellence (NICE)
recommends universal screening for Lynch syndrome in people
with colorectal cancer (10). Universal screening was identified
to be a cost-effective use of healthcare resources because of the
number of colorectal cancers prevented in family members who
are also found to carry Lynch syndrome (11). Screening women
with endometrial cancer provides a further opportunity to save
lives from Lynch syndrome-associated cancer (12), however, the
costs associated with this screening strategy are not known. The
aim of this study was to identify and quantify the resource use
and costs associated with different diagnostic strategies relevant
to screening for Lynch syndrome in an unselected endometrial
cancer population.
Abbreviations: NGS, Next generation sequencing; MSI, Microsatellite instability;
MSI-H, Microsatellite instability high; IHC, Immunohistochemistry; MMR,
Mismatch repair; NICE, National Institute for Health and Care Excellence; NHS,
National Health Service, England.
METHODS
Amicro-costing study was performed to identify the resource use
and cost per patient of four diagnostic testing strategies for Lynch
syndrome in an unselected endometrial cancer population. The
study assumed the perspective of the National Health Service
(NHS) in England. The direct costs associated with providing
each diagnostic testing strategy were identified. The time horizon
for identifying the relevant resources use in this study started with
the process of gaining informed consent for any Lynch syndrome
testing and ended with generating a report of the final diagnostic
test result.
Diagnostic Testing Strategies
Four Lynch syndrome testing technologies that reflect
current and emerging national clinical practice (10) were
included in this study: microsatellite instability (MSI)
testing; immunohistochemistry (IHC); MLH1 promoter
hypermethylation pyrosequencing (methylation) testing; and
next generation sequencing (NGS) (13). The technologies
used to produce each diagnostic test were conceptualized
into representative clinical pathways using a decision tree to
provide a structured approach to represent how each technology
would form part of a diagnostic testing strategy for a defined
population of women with suspicion of Lynch syndrome.
The relevant outcome of testing was defined as either Lynch
syndrome diagnosed or not diagnosed. The four diagnostic
testing strategies were:
Strategy 1: Initial tumor triage withMSI followed by germline
NGS testing for pathogenic variants of the MMR genes for all
those found to have microsatellite instability (MSI-H).
Strategy 2: Initial tumor triage with MSI followed by reflex
MLH1 methylation testing for MSI-H tumors, and germline
NGS testing for women where the tumor MLH1 methylation
test shows no hypermethylation.
Strategy 3: Initial tumor triage with IHC followed by reflex
MLH1 methylation testing for tumors with MLH1 loss.
Germline NGS testing for pathogenic variants of the MMR
genes for all women whose tumors show MSH2, MSH6 or
PMS2 loss, or MLH1 loss where the MLH1 methylation test
shows no hypermethylation.
Strategy 4: No initial tumor triage. All women with
endometrial cancer undergo direct germline NGS testing for
pathogenic variants of the MMR genes.
The decision tree (Figure 1) was conceptualized through
discussion with a panel of 10 local and national experts. These
experts included two consultant histopathologists, three senior
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FIGURE 1 | Decision tree outlining the diagnostic strategies for screening endometrial cancer for Lynch syndrome in this study.
(>band 8a Agenda For Change pay scale) clinical laboratory
scientists, two consultant gynecological oncology surgeons,
two consultant clinical geneticists, and one consultant genetic
pathologist. The decision tree represented the proportion of cases
testing positive with each technology and subsequent impact
on the need to conduct further testing. The input values for
the decision tree were informed by a pragmatic review of the
literature (see Supplementary Appendix 1), which identified the
relevant studies to inform the probability of a positive or negative
test result in each scenario.
Identifying Resource Use
The use of resources was identified for each diagnostic testing
strategy, assuming the NHS perspective. Resource use included
clinical and laboratory staff time, capital equipment, and
laboratory consumables.
Clinical and laboratory staff time was collected using a
prospective study at a large tertiary genetics and gynecology
oncology surgical referral center in the North West of England
between 2015 and 2017. The study was approved by the North
West Research Ethics Committee (15/NW/0733) and all patients
gave written, informed consent to participate. Non-participant
direct observation was used to identify the time members of
staff dedicated to each element of the diagnostic test process. A
single observer recorded timings with a stopwatch over multiple
rounds of observation between 2015 and 2017, using a structured
data collection tool and recording information on sample batch
size and staff pay grade. Participant direct observation was used
to record the process of obtaining informed consent for Lynch
syndrome testing. Because this was done as part of a research
study, all participants were consented prior to any testing. The
consent process included discussion about the various tumor
tests (MSI, IHC, methylation testing) and indicative germline
Lynch syndrome testing.
Hospital information systems were used to derive resource
use on capital equipment including diagnostic platforms. Total
capital throughput for a given piece of equipment was identified
as the total annual number of samples it processed. Total Lynch
syndrome-associated capital throughput for a given piece of
equipment was identified as the total annual number of Lynch
syndrome-associated samples it processed, assuming all newly
diagnosed endometrial cancer patients were offered testing.
Consumables were identified from laboratory standard
operating procedures and through completion of a structured
data collection form by seven laboratory staff who routinely test
patients for Lynch syndrome, including biomedical technicians,
a consultant clinical scientist, a principal clinical scientist, and
clinical genetics technicians.
Collating Unit Costs
The unit costs (UK sterling; £) for consumables and equipment
were extracted from published list prices, or hospital invoices
where list prices were unavailable. The unit costs for staff labor
were defined as cost per minute using the midpoints of salary
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grades as per NHS Agenda for Change or the British Medical
Association’s Hospital Doctor pay scales (see Table S4). The price
year for unit costs was standardized at 2017. Table S2 shows the
complete list of unit costs and sources.
Data Analysis
All analysis was carried out using Microsoft Corporation
software program Microsoft Office Excel 2011. The base case
analysis calculated the direct medical costs of each of the four
diagnostic testing strategies shown in Figure 1. The costs were
calculated for testing a single sample by multiplying the relevant
unit cost (see Table S2) with the relevant items and quantities of
resource use.
One-way sensitivity analysis was used to identify the impact
of using different estimates for the probability of a positive or
negative test result for each diagnostic testing strategy. The ranges
of the probability input values were informed by a pragmatic
literature search (Supplementary Appendix 1, Table S1) and
used to assess the effect different test outcomes would have on
the overall cost of each strategy. Two separate scenario analyses
explored the impact of the timing of consent on the cost of
each diagnostic testing strategy. Two scenarios were explored
to understand the cost if consent was taken before any testing,
compared with a scenario in which consent was only taken for
those needing germline NGS testing.
RESULTS
Table 1 shows the individual quantities of resource use for MSI,
IHC, MLH1 methylation testing, and NGS, which were used to
calculate the total costs incurred per patient for each of the four
diagnostic testing strategies.
Tumor triage with MSI and reflex MLH1 methylation testing
followed by germline NGS of women with likely Lynch syndrome
(Strategy 2) was the cheapest at £42.01 per patient. Tumor
triage with IHC and reflex MLH1 methylation testing of MLH1
protein-deficient cancers followed by NGS of women with likely
Lynch syndrome (Strategy 3) cost £45.68. Tumor triage with MSI
followed by NGS of all women found to have MSI-H tumors
(Strategy 1) cost £78.95. Immediate germline NGS of all women
with endometrial cancer (Strategy 4) cost £176.24.
The cost of consenting a woman for Lynch syndrome testing
was calculated from 269 directly observed episodes. Two women
declined Lynch syndrome testing. On average, the process
of gaining consent took 7min and 39 s (SD: 5min, 16 s) of
consultant time. This cost an average of £5.32.
Immediate, unselected germline NGS testing for pathogenic
variants of theMMR genes in all women with endometrial cancer
was the most expensive testing strategy. Consumables were an
expensive component, costing £115.14 overall, including DNA
extraction. As germline DNA is required, it was assumed that all
samples for NGS would require de-novo DNA extraction from
blood. Equipment costs were expensive for NGS, at £5.43 per
sample tested. Labor costs were also relatively high due to the
complexity of data interpretation, costing £50.35 per sample.
Strategies one to three involved the use of tumor-based triage
with IHC and MSI. Tumor based triage by IHC was cheaper
than MSI (£21.17 vs. £27.67). The most expensive resource was
consumables (£12.23 vs. £19.19 for IHC and MSI, respectively).
Labor costs were similar (£8.51 vs. £8.30 for IHC and MSI,
respectively); this was despite the need for a consultant grade
doctor to interpret the IHC results, because the per-sample time
was relatively short. Equipment costs were more expensive for
IHC at £0.43 per sample due to use of a dedicated staining
platform and associated maintenance costs. These costs were
cheaper forMSI testing at £0.18 per sample, using a commercially
available kit.
MLH1 methylation testing was a component of diagnostic
strategies two and three, and cost £20.60 and £28.41, respectively,
when needed. Methylation testing was cheaper in the context of
Strategy two because DNA extraction had already been done for
the initial MSI testing. Methylation testing included labor costs
at £3.94 (including DNA extraction) or £2.07 (excluding DNA
extraction), and equipment costs at £0.23 per sample. Therefore,
assuming 30% of endometrial tumors are MSI-H, methylation
testing saves £36.95 per patient tested by this strategy because it
removes the need for expensive germline NGS by the majority.
Incorporating methylation testing in Strategy three (assuming
35% of samples show MMR loss, of which 27% is due to loss of
MLH1) reduces the cost of this strategy by £35.21 per patient.
Sensitivity Analysis
One-way sensitivity analysis explored the potential variation
in the cost of each diagnostic testing strategy using
pessimistic and optimistic values for the probability of a
positive test result and need for subsequent testing (see
Supplementary Appendix 2, Table S3). Depending on the
source of data, between 22 to 30% of cases in Strategy one require
subsequent germline NGS testing (14, 15). The incorporation
of MLH1 methylation testing in Strategy two reduces this
proportion to 5–10% of cases (14–16). For Strategy three, MLH1
loss is observed in 16–27% of cases (15, 17), but ∼93% of these
are due to MLH1 hypermethylation, meaning that just 7% of
those women with MLH1 loss by IHC require germline NGS
testing for Lynch syndrome (15). Non-MLH1 protein loss by
IHC is seen in 6–8% endometrial tumors and all of these require
germline NGS testing (Table S3).
The range of women who were found to carry a pathogenic
variant associated with Lynch syndrome in Strategy 2 is between
1 and 3% of cases (14, 15). For Strategy three, 11% of those
with MLH1 loss and no MLH1 hypermethylation tested by NGS
will have a pathogenic variant in MLH1, according to current
literature (15). Twenty percent of those with MSH2, MSH6, or
PMS2 loss by IHC will be found to carry pathogenic variants
of MSH2, MSH6, or PMS2 (15). Varying the proportions of
women requiring subsequent tests in the decision tree, based on
pessimistic and optimistic values for the probability of a positive
test result in, showed no significant impact on the expected costs
for each diagnostic testing strategy.
A scenario analysis explored the impact of the timing of
taking consent for Lynch syndrome testing. If consent was only
taken at the point of germline NGS testing, the overall cost for
Strategy one is cheaper at £75.22 per patient. The overall cost
of Strategies two, three, and four would be £36.95, £40.89, and
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£176.24, respectively. Therefore, taking consent only at the point
of germline NGS testing saved the Strategy cost by around £4.52
per person, on average (range £3.73–£5.06).
DISCUSSION
This study presents the first comprehensive micro-costing
analysis of diagnostic strategies for Lynch syndrome testing in
endometrial cancer. In total, four pathways were quantified,
reflecting the diagnostic strategies relevant to current clinical
practice in the UK. The expected costs were £42.01 or £45.68
per case, respectively if MSI or IHC were used for tumor
triage and reflex MLH1 methylation testing was followed
by germline NGS of women with likely Lynch syndrome.
Immediate germline NGS for all women with endometrial cancer
cost £176.24.
Goverde et al. (18) cites estimates close to our calculated
costs for three of the diagnostic strategies (MSI e89, IHC e135,
MLH1 hypermethylation e99). However, the cost of NGS was
considerably more expensive than our calculation, at e2152 per
test (18). Our findings indicate the cost of Lynch syndrome
testing in endometrial cancer is sometimes considerably cheaper
than previously described. Published cost effectiveness studies to
date may have overestimated the cost of Lynch syndrome testing
in clinical practice (18–20). In a published model-based cost-
effectiveness analysis of screening for Lynch Syndrome in people
with colorectal cancer, the estimated unit cost for IHC was £210
and £202 for MSI and £136 per test forMLH1 hypermethylation.
Using NGS for four MMR gene NGS was estimated to cost
between £650 and £860 (21). These unit costs were derived
from expert estimates from the UK Genetic Testing Network
(21). Three model-based cost-effectiveness analysis of unselected
endometrial cancer screening for Lynch syndrome base their
analysis on these estimates or on insurance charges (18–20). Two
of these published studies concluded that using tumor triage with
IHC and reflex MLH1 methylation testing of MLH1 protein-
deficient cancers followed by NGS of women with likely Lynch
syndrome (our strategy 3) was cost effective for Lynch syndrome
screening, despite using higher costs in their modeling(18, 20).
One study that used the highest estimated cost for the diagnostic
tests indicated that Lynch syndrome screening was not cost-
effective (22). These findings are consistent with the observation
of Grosse (23) who indicated that the assumed cost of the
diagnostic strategy is a key driver of the relative cost-effectiveness
of testing for Lynch syndrome (23).
Ours is the first micro-costing study of Lynch syndrome
testing in endometrial cancer. Previous micro-costing studies of
genetic-based tests have only measured the costs of unselected
sequencing of samples (akin to our strategy 4), without
quantifying the impact of using tumor based triage (24,
25). Griffith et al (26) micro-costed two gene (MLH1/MSH2)
mutational screening at £1212.17, but this study pre-dates
NGS technology and is therefore no longer relevant to clinical
practice (26).
Our study was set within a gynecological oncology center
comparable with other centers in the UK. It benefited from
prospective recruitment and therefore direct observation of
269 patient consent episodes. All but two of 269 patients
agreed to Lynch syndrome testing. This is higher than expected
from the literature and may reflect testing within a publically-
funded healthcare system rather than one based on health
insurance, where a positive test result is likely to impact
future insurance premiums (27). Taking informed consent
is a variable process as each patient encounter is unique;
understanding the uncertainty of the process was possible using
the multiple observations. We also used direct observations for
all non-automated step in the laboratory testing process. The
decision tree was conceptualized by a panel of experts with
representation from across the diagnostic pathway, therefore
reflecting current clinical practice. The sensitivity analysis drew
on multiple high-quality studies sourced through an extensive
literature search.
To the best of our knowledge, ours may be the first study
to micro-cost NGS testing for any indication. Our micro-
costing study indicated that analysis of raw NGS output is time
consuming and requires considerable expertise. Indeed, 80% of
labor costs, and 25% of the overall costs for NGS, were spent
on data analysis. It is departmental policy for all NGS results
to be analyzed twice, first by an agenda for change (AFC)
band 5 and then a band 7 member of staff. Reports are then
authorized by a senior member of staff (band 8a). This is for
quality assurance purposes and is in keeping with international
recommendations (28).
Another key finding was the impact of the timing of patient
consent on the overall costs of testing. Consent is fundamental
to germline genetic testing since patients have the absolute
right to refuse to be tested (29). However, the point at which
consent is sought has a considerable impact on the overall cost
of Lynch syndrome testing. Consent taken prior to any testing
would add this cost uniformly to all strategies. However, if
consent were taken only at the point of germline NGS analysis,
only a small proportion of women (5–30%) would need to
be consented. Somatic tumor analyses are commonplace in
histopathology, for example p53 IHC. Consent is not taken for
such tests because they are integral to accurate diagnosis, as
well as informing prognosis and treatment planning. Crucially
such tests make inferences about cancer biology and not the
individual’s genome. Such an argument could easily be applied
for tumor-based Lynch syndrome testing as such tests merely
stratify an individual’s risk of having Lynch syndrome and
do not diagnose a germline condition. Moving the consent
to the point of germline testing would require an additional
face-to-face meeting with the patient. This could take place in
the context of routine cancer follow-up, therefore mitigating
the need for an additional appointment and its associated
costs. However, any impact of moving consent to the point
of germline testing on uptake and health state utility cannot
be ascertained from our data, since all patient consents were
taken at recruitment into the study, before any testing was
carried out.
Our study is limited by the fact that all observations originate
from a single site and therefore may not be generalizable.
Their application outside England is difficult to assess given
Frontiers in Oncology | www.frontiersin.org 7 February 2019 | Volume 9 | Article 61
Ryan et al. Micro-Costs of Lynch Syndrome Screening
geographically distinct populations, diverse health systems
and variable costs. We have not accounted for failed tests
that need to be repeated at additional cost. It was also
not possible to analyse capital costs like heating, lighting,
and rent. Capital costs are not insignificant, however the
confidentiality implicit in private finance initiatives prevented
their incorporation in our analysis. Therefore, the true cost
of Lynch syndrome testing is likely to lie somewhere between
the cost identified by this micro-costing study, which was as
thorough as possible but not exhaustive in its pursuit of all
applied costs, and the well-sourced expert estimates, which over-
estimate costs to ensure the service does not operate at a net
loss (30).
A further limitation of our work is that the proportion of
positive test results used in our decision tree originated from
populations studied outside the UK and therefore may not be
fully representative of the local situation. This is of particular
concern given that such patients were tested within insurance-
based healthcare systems, potentiating a selection bias in which
high risk individuals decline testing to avoid would-be increased
premiums. This limitation is unavoidable given the complete lack
of UK data relating to the prevalence of Lynch syndrome in
endometrial cancer patients.
The extrapolation of our data to inform Lynch syndrome
testing in colorectal cancer patients is problematic given their use
of BRAF V600E as a proxy ofMLH1 promoter hypermethylation
in tumor-based triage (31). Furthermore, it is not clear if the
proportions used in our decision tree are transferable to a
colorectal cancer population. Nonetheless, the costs of IHC, MSI,
and NGS testing (as opposed to the cost of testing strategies) are
directly transferable and could be used to improve the robustness
of model-based cost effectiveness analysis of Lynch syndrome
testing in colorectal cancer.
Regarding tumor-based triage, a strategy using MSI analysis
is marginally cheaper than one using IHC as the primary test
(£42.01 vs. £45.68). A £3.67 saving per tumor would save
the NHS over £33,000 annually, were all 9,000 new diagnoses
of endometrial cancer tested for Lynch syndrome. However,
the choice of tumor triage is complex and beyond a simple
cost comparison; this is especially the case when the cost
difference is marginal. Both methods have equitable sensitivity
and specificity according to the literature (11). IHC has the
advantage of identifying the likely mutated gene, which can
aid the subsequent interpretation of sequencing data (32).
IHC can be performed in most histopathology departments,
whereas MSI requires specialist laboratories. IHC is thought
to be more sensitive in the case of those carrying a MSH6
pathogenic variant, where tumors may not be MSI-H (33).
However, interpretation of MMR expression patterns requires
consultant pathology expertise, and only MSI can identify
missense pathogenic variants in MMR genes whereby the
protein is expressed but is not functional (34). The choice
of tumor triage depends on the availability of local services,
expertise, and infrastructure; these data do not infer that any
one strategy is clinically superior to another for the diagnosis of
Lynch syndrome.
The importance of our work is its ability to inform healthcare
policy. There is a growing call for screening all endometrial
cancer patients for Lynch syndrome (12, 35). A potential barrier
to the transition from expert opinion to clinical application is
cost. To date there have been no micro-costing data available
to inform policy makers as to the actual costs of Lynch
syndrome testing in the UK. As outlined above, the current
estimated costs might be prohibitively high and thus impede
the implementation of Lynch syndrome testing in endometrial
cancer. Our data should prompt healthcare providers to look at
this again.
CONCLUSION
We present a micro-costing study for Lynch syndrome testing
in unselected endometrial cancer patients from a large tertiary
referral center in the North West of England. The use of
tumor triage with MSI and reflex MLH1 methylation testing
is the cheapest strategy at £42.01 per case. Substituting MSI
for IHC as the initial tumor-based triage increases costs
marginally to £45.68. Moving the point of consent for Lynch
syndrome testing to just before germline testing reduces the
costs of those strategies that incorporate tumor triage. NGS
panel testing is considerably cheaper than current estimates at
£176.24 per test. The next phase is to use these estimates in
model-based cost-effectiveness analysis to understand the relative
value of a national Lynch syndrome-testing programme for
endometrial cancer.
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